BRIEF published on 10/13/2026 at 18:15, 18 days 6 hours ago Medincell Secures €41.8 Million in Non-Dilutive Financing Debt Maturity Non-dilutive Financing Biopharmaceuticals European Investment Bank Medincell
BRIEF published on 10/13/2026 at 18:15, 18 days 6 hours ago Medincell strengthens its financing with a new non-dilutive loan Treasury Funding Biopharmaceutical Medincell Non-dilutable
PRESS RELEASE published on 10/13/2026 at 18:10, 18 days 6 hours ago Inside Information / Other news releases Medincell secures €13.8 million non-dilutive financing, totaling €41.8 million. Debt maturity extended through 2031. No equity instruments used for financing Debt Maturity Non-dilutive Financing Bpifrance Medincell European Commercial Banks
BRIEF published on 10/09/2026 at 15:03, 22 days 9 hours ago Medincell shares resume trading on Euronext Paris FDA Euronext Medincell Teva Olanzapine LAI
BRIEF published on 10/09/2026 at 15:03, 22 days 9 hours ago Medincell Resumes Trading on Euronext Paris Euronext Paris FDA Approval Trading Resumption Medincell BEPO Technology
PRESS RELEASE published on 10/09/2026 at 14:58, 22 days 9 hours ago Inside Information / Other news releases Medincell resumes trading on Euronext Paris after temporary suspension. The company specializes in long-acting injectable treatments using innovative technologies Innovation Euronext Paris Trading Medincell Long-acting Injectable Treatments
BRIEF published on 10/09/2026 at 14:01, 22 days 10 hours ago Medincell receives FDA approval for WELTRUZA™ FDA Schizophrenia Medincell Olanzapine WELTRUZA™
PRESS RELEASE published on 10/09/2026 at 13:56, 22 days 10 hours ago Inside Information / Other news releases Medincell achieves major milestone with U.S. FDA approval of WELTRUZA™ (olanzapine), offering a new treatment option for adults with schizophrenia FDA Approval Schizophrenia Medincell Long-acting Injectable WELTRUZA
BRIEF published on 10/09/2026 at 09:43, 22 days 14 hours ago Medincell Temporarily Suspends Trading on Euronext Paris Euronext Paris Biopharmaceuticals Trading Suspension Medincell BEPO Technology
PRESS RELEASE published on 10/09/2026 at 09:38, 22 days 14 hours ago Inside Information / Other news releases Medincell temporarily suspends trading of its shares on Euronext Paris pending a press release, focusing on long-acting injectable treatments and innovative therapeutic candidates Euronext Paris Suspension Therapeutic Candidates Medincell Long-acting Injectable Treatments
Published on 10/30/2026 at 23:35, 1 day ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 5 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 8 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/31/2026 at 16:35, 7 hours 54 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 1 hour ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 1 day 5 hours ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 1 day 1 hour ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 1 day 12 hours ago Capital increase through exercise of subscription rights
